Dendritic Cells in the Cross Hair for the Generation of Tailored Vaccines

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Jul 13

PMID 29997628

Citations 12

Authors

Laura Gornati

Ivan Zanoni

Francesca Granucci

Affiliations

Soon will be listed here.

Abstract

Vaccines represent the discovery of utmost importance for global health, due to both prophylactic action to prevent infections and therapeutic intervention in neoplastic diseases. Despite this, current vaccination strategies need to be refined to successfully generate robust protective antigen-specific memory immune responses. To address this issue, one possibility is to exploit the high efficiency of dendritic cells (DCs) as antigen-presenting cells for T cell priming. DCs functional plasticity allows shaping the outcome of immune responses to achieve the required type of immunity. Therefore, the choice of adjuvants to guide and sustain DCs maturation, the design of multifaceted vehicles, and the choice of surface molecules to specifically target DCs represent the key issues currently explored in both preclinical and clinical settings. Here, we review advances in DCs-based vaccination approaches, which exploit direct DCs targeting and activation options. We also discuss the recent findings for efficient antitumor DCs-based vaccinations and combination strategies to reduce the immune tolerance promoted by the tumor microenvironment.

Citing Articles

Prophylactic and therapeutic vaccine development: advancements and challenges.

Weerarathna I, Doelakeh E, Kiwanuka L, Kumar P, Arora S Mol Biomed. 2024; 5(1):57.

PMID: 39527305 PMC: 11554974. DOI: 10.1186/s43556-024-00222-x.

Mechanism of Innate Immune Response Induced by Saponin Active Fraction Using C2C12 Myoblasts.

Du J, Meng X, Ni T, Xiong B, Han Z, Zhu Y Vaccines (Basel). 2023; 11(10).

PMID: 37896979 PMC: 10610972. DOI: 10.3390/vaccines11101576.

A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.

Hu L, Sun J, Wang Y, Tan D, Cao Z, Gao L Vaccines (Basel). 2023; 11(6).

PMID: 37376434 PMC: 10302808. DOI: 10.3390/vaccines11061045.

Novel nanoadjuvants balance immune activation with modest inflammation: implications for older adult vaccines.

Ross K, Tingle A, Senapati S, Holden K, Wannemuehler M, Mallapragada S Immun Ageing. 2023; 20(1):28.

PMID: 37344886 PMC: 10283283. DOI: 10.1186/s12979-023-00349-5.

SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.

Sunagar R, Singh A, Kumar S Vaccines (Basel). 2023; 11(4).

PMID: 37112761 PMC: 10143972. DOI: 10.3390/vaccines11040849.

References

Guo M, Gong S, Maric S, Misulovin Z, Pack M, Mahnke K . A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol. 2000; 61(8):729-38. DOI: 10.1016/s0198-8859(00)00144-0. View

Mahnke K, Guo M, Lee S, Sepulveda H, Swain S, Nussenzweig M . The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol. 2000; 151(3):673-84. PMC: 2185598. DOI: 10.1083/jcb.151.3.673. View

Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E . Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol. 2001; 2(9):882-8. DOI: 10.1038/ni0901-882. View

Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M . Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001; 194(6):769-79. PMC: 2195961. DOI: 10.1084/jem.194.6.769. View

Becker T, Hartl F, Wieland F . CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol. 2002; 158(7):1277-85. PMC: 2173242. DOI: 10.1083/jcb.200208083. View

Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig M, Steinman R . Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002; 196(12):1627-38. PMC: 2196060. DOI: 10.1084/jem.20021598. View

Steinman R, Hawiger D, Nussenzweig M . Tolerogenic dendritic cells. Annu Rev Immunol. 2003; 21:685-711. DOI: 10.1146/annurev.immunol.21.120601.141040. View

Kao J, Gong Y, Chen C, Zheng Q, Chen J . Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol. 2003; 170(7):3806-11. DOI: 10.4049/jimmunol.170.7.3806. View

Itano A, McSorley S, Reinhardt R, Ehst B, Ingulli E, Rudensky A . Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity. 2003; 19(1):47-57. DOI: 10.1016/s1074-7613(03)00175-4. View

10.

Bonifaz L, Bonnyay D, Charalambous A, Darguste D, Fujii S, Soares H . In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004; 199(6):815-24. PMC: 2212731. DOI: 10.1084/jem.20032220. View

11.

Heath W, Belz G, Behrens G, Smith C, Forehan S, Parish I . Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev. 2004; 199:9-26. DOI: 10.1111/j.0105-2896.2004.00142.x. View

12.

Granucci F, Zanoni I, Pavelka N, van Dommelen S, Andoniou C, Belardelli F . A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med. 2004; 200(3):287-95. PMC: 2211974. DOI: 10.1084/jem.20040370. View

13.

Waeckerle-Men Y, Groettrup M . PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev. 2004; 57(3):475-82. DOI: 10.1016/j.addr.2004.09.007. View

14.

Sixt M, Kanazawa N, Selg M, Samson T, Roos G, Reinhardt D . The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity. 2005; 22(1):19-29. DOI: 10.1016/j.immuni.2004.11.013. View

15.

Kissenpfennig A, Henri S, Dubois B, Laplace-Builhe C, Perrin P, Romani N . Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity. 2005; 22(5):643-54. DOI: 10.1016/j.immuni.2005.04.004. View

16.

Laxmanan S, Robertson S, Wang E, Lau J, Briscoe D, Mukhopadhyay D . Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun. 2005; 334(1):193-198. PMC: 4495768. DOI: 10.1016/j.bbrc.2005.06.065. View

17.

Legler D, Krause P, Scandella E, Singer E, Groettrup M . Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol. 2006; 176(2):966-73. DOI: 10.4049/jimmunol.176.2.966. View

18.

Finlay B, McFadden G . Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell. 2006; 124(4):767-82. DOI: 10.1016/j.cell.2006.01.034. View

19.

Chen M, Wang Y, Wang Y, Huang L, Sandoval H, Liu Y . Dendritic cell apoptosis in the maintenance of immune tolerance. Science. 2006; 311(5764):1160-4. DOI: 10.1126/science.1122545. View

20.

Boscardin S, Hafalla J, Masilamani R, Kamphorst A, Zebroski H, Rai U . Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med. 2006; 203(3):599-606. PMC: 2118236. DOI: 10.1084/jem.20051639. View